Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in RCC Following an Immune Checkpoint Inhibitor The Phase 3 TiNivo-2 Study : Episode 3

VEGFR-TKI Tivozanib: Rational Treatment Selection Post-ICI Progression

April 3, 2025

By Sumanta Pal, MD, FASCO
Benjamin Gerendash, MSN, RN, AGACNP-BC

Opinion

Video

Experts discuss the rational treatment selection of the VEGFR-tyrosine kinase inhibitor (TKI) tivozanib following progression after immune checkpoint inhibitor (ICI) therapy.

EP: 1.First-Line RCC Treatment in 2025: Navigating the Evolving Therapeutic Landscape

EP: 2.Sequencing Strategies in RCC: Optimizing Treatment Selection After IO-Based Therapy

Now Viewing

EP: 3.VEGFR-TKI Tivozanib: Rational Treatment Selection Post-ICI Progression

EP: 4.Tivozanib Monotherapy Efficacy Profile and Clinical Management Strategies in Advanced RCC

EP: 5.Optimizing VEGFR-TKI Therapy: Perspectives on Patient Selection and Management Strategies in Clinic

EP: 6.TiNivo-2 Phase 3 Trial: Survival Data and Practical Approaches to Dose Management in Practice

EP: 7.Quality of Life and Treatment Experience: Patient-Reported Outcomes from TiNivo-2

EP: 8.Optimizing RCC Treatment: Integrating Patient-Reported Outcomes and Clinician Insights

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!

Latest Conference Coverage

Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care

Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC

Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs

Safety Management With Amivantamab Plus Lazertinib in NSCLC

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777